VEGFA and non-small cell lung carcinoma: Although clinical experience with combined VEGF/EGFR inhibition is limited, in a recent phase I/II trial of patients with previously treated non-small-cell lung cancer (NSCLC; nonsquamous histology) the combination of erlotinib and bevacizumab showed encouraging antitumour activity (Herbst et al, 2005).